11 March 2024 DIMERIX SUCCESSFULLY PASSES EFFICACY INTERIM ANALYSIS IN ACTION3 PHASE 3 STUDY FOR FSGS KIDNEY DISEASE 0 minute read Pharma/Biotech By Cate Swannell Previous Post Next Post